125 related articles for article (PubMed ID: 26587694)
1. Pilot study on the detection of antiandrogen resistance using serial diffusion-weighted imaging of bone metastases in prostate cancer.
Reischauer C; Koh DM; Froehlich JM; Patzwahl R; Binkert CA; Gutzeit A
J Magn Reson Imaging; 2016 Jun; 43(6):1407-16. PubMed ID: 26587694
[TBL] [Abstract][Full Text] [Related]
2. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps--initial observations.
Reischauer C; Froehlich JM; Koh DM; Graf N; Padevit C; John H; Binkert CA; Boesiger P; Gutzeit A
Radiology; 2010 Nov; 257(2):523-31. PubMed ID: 20829534
[TBL] [Abstract][Full Text] [Related]
3. Changes in diffusion-weighted images for visualizing prostate cancer during antiandrogen therapy: preliminary results.
Nemoto K; Tateishi T; Ishidate T
Urol Int; 2010; 85(4):421-6. PubMed ID: 21051871
[TBL] [Abstract][Full Text] [Related]
4. Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.
Perez-Lopez R; Mateo J; Mossop H; Blackledge MD; Collins DJ; Rata M; Morgan VA; Macdonald A; Sandhu S; Lorente D; Rescigno P; Zafeiriou Z; Bianchini D; Porta N; Hall E; Leach MO; de Bono JS; Koh DM; Tunariu N
Radiology; 2017 Apr; 283(1):168-177. PubMed ID: 27875103
[TBL] [Abstract][Full Text] [Related]
5. Diffusion-weighted imaging to evaluate for changes from androgen deprivation therapy in prostate cancer.
Kim AY; Kim CK; Park SY; Park BK
AJR Am J Roentgenol; 2014 Dec; 203(6):W645-50. PubMed ID: 25415730
[TBL] [Abstract][Full Text] [Related]
6. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection.
Reinsberg SA; Payne GS; Riches SF; Ashley S; Brewster JM; Morgan VA; deSouza NM
AJR Am J Roentgenol; 2007 Jan; 188(1):91-8. PubMed ID: 17179350
[TBL] [Abstract][Full Text] [Related]
7. Early treatment response in non-small cell lung cancer patients using diffusion-weighted imaging and functional diffusion maps--a feasibility study.
Reischauer C; Froehlich JM; Pless M; Binkert CA; Koh DM; Gutzeit A
PLoS One; 2014; 9(10):e108052. PubMed ID: 25289671
[TBL] [Abstract][Full Text] [Related]
8. Differentiation of central gland prostate cancer from benign prostatic hyperplasia using monoexponential and biexponential diffusion-weighted imaging.
Liu X; Zhou L; Peng W; Wang C; Wang H
Magn Reson Imaging; 2013 Oct; 31(8):1318-24. PubMed ID: 23791546
[TBL] [Abstract][Full Text] [Related]
9. Application of Diffusion Weighted Imaging in Prostate Cancer Bone Metastasis: Detection and Therapy Evaluation.
Gong XQ; Tao YY; Wang R; Liu N; Huang XH; Zheng J; Yang C; Yang L; Zhang XM
Anticancer Agents Med Chem; 2021; 21(15):1950-1956. PubMed ID: 33461473
[TBL] [Abstract][Full Text] [Related]
10. Diffusion in prostate cancer detection on a 3T scanner: How many b-values are needed?
de Perrot T; Scheffler M; Boto J; Delattre BM; Combescure C; Pusztaszeri M; Tille JC; Iselin C; Vallée JP
J Magn Reson Imaging; 2016 Sep; 44(3):601-9. PubMed ID: 26914964
[TBL] [Abstract][Full Text] [Related]
11. Texture analysis of apparent diffusion coefficient maps for treatment response assessment in prostate cancer bone metastases-A pilot study.
Reischauer C; Patzwahl R; Koh DM; Froehlich JM; Gutzeit A
Eur J Radiol; 2018 Apr; 101():184-190. PubMed ID: 29571795
[TBL] [Abstract][Full Text] [Related]
12. Anterior Prostate Cancer: Diagnostic Performance of T2-Weighted MRI and an Apparent Diffusion Coefficient Map.
Shinmoto H; Tamura C; Soga S; Okamura T; Horiguchi A; Asano T; Kaji T
AJR Am J Roentgenol; 2015 Aug; 205(2):W185-92. PubMed ID: 26204306
[TBL] [Abstract][Full Text] [Related]
13. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness.
Vargas HA; Akin O; Franiel T; Mazaheri Y; Zheng J; Moskowitz C; Udo K; Eastham J; Hricak H
Radiology; 2011 Jun; 259(3):775-84. PubMed ID: 21436085
[TBL] [Abstract][Full Text] [Related]
14. Pilot Study of the Use of Hybrid Multidimensional T2-Weighted Imaging-DWI for the Diagnosis of Prostate Cancer and Evaluation of Gleason Score.
Sadinski M; Karczmar G; Peng Y; Wang S; Jiang Y; Medved M; Yousuf A; Antic T; Oto A
AJR Am J Roentgenol; 2016 Sep; 207(3):592-8. PubMed ID: 27352026
[TBL] [Abstract][Full Text] [Related]
15. A Multicompartmental Diffusion Model for Improved Assessment of Whole-Body Diffusion-weighted Imaging Data and Evaluation of Prostate Cancer Bone Metastases.
Conlin CC; Feng CH; Digma LA; Rodríguez-Soto AE; Kuperman JM; Rakow-Penner R; Karow DS; White NS; Seibert TM; Hahn ME; Dale AM
Radiol Imaging Cancer; 2023 Jan; 5(1):e210115. PubMed ID: 36705559
[TBL] [Abstract][Full Text] [Related]
16. Risk Stratification of Prostate Cancer Using the Combination of Histogram Analysis of Apparent Diffusion Coefficient Across Tumor Diffusion Volume and Clinical Information: A Pilot Study.
Zhang Z; Xu H; Xue Y; Li J; Ye Q
J Magn Reson Imaging; 2019 Feb; 49(2):556-564. PubMed ID: 30173421
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric MR diffusion-weighted imaging for monitoring the ultra-early treatment effect of sorafenib in human hepatocellular carcinoma xenografts.
Chen X; Ma Z; Huang Y; He L; Liang C; Shi C; Zhang Z; Liang C; Liu Z
J Magn Reson Imaging; 2017 Jul; 46(1):248-256. PubMed ID: 27783444
[TBL] [Abstract][Full Text] [Related]
18. Diffusion-weighted MRI treatment monitoring of primary hypofractionated proton and carbon ion prostate cancer irradiation using raster scan technique.
Wolf MB; Edler C; Tichy D; Röthke MC; Schlemmer HP; Herfarth K; Bonekamp D
J Magn Reson Imaging; 2017 Sep; 46(3):850-860. PubMed ID: 28152251
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Value of Whole-Body DWI With Background Body Suppression Plus Calculation of Apparent Diffusion Coefficient at 3 T Versus
Sun W; Li M; Gu Y; Sun Z; Qiu Z; Zhou Y
AJR Am J Roentgenol; 2020 Feb; 214(2):446-454. PubMed ID: 31799866
[No Abstract] [Full Text] [Related]
20. Use of diffusion-weighted, intravoxel incoherent motion, and dynamic contrast-enhanced MR imaging in the assessment of response to radiotherapy of lytic bone metastases from breast cancer.
Gaeta M; Benedetto C; Minutoli F; D'Angelo T; Amato E; Mazziotti S; Racchiusa S; Mormina E; Blandino A; Pergolizzi S
Acad Radiol; 2014 Oct; 21(10):1286-93. PubMed ID: 25088834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
